
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical Net Debt 2011-2025 | AFIB
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | 9.17 M | 16.7 M | 25.1 M | 31.7 M | 16.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.7 M | 9.17 M | 18.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.86 | -3.26 % | $ 134 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Abiomed
ABMD
|
-227 M | - | - | $ 17.2 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 307.92 | -1.93 % | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 45.13 | -2.67 % | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Abbott Laboratories
ABT
|
5.26 B | $ 125.1 | 1.48 % | $ 218 B | ||
|
Boston Scientific Corporation
BSX
|
8.64 B | $ 92.34 | 0.64 % | $ 136 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 2.56 | 8.94 % | $ 95.5 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 0.92 | -4.72 % | $ 14.8 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 96.35 | -1.06 % | $ 1.22 B | ||
|
OrthoPediatrics Corp.
KIDS
|
31.3 M | $ 17.7 | -3.46 % | $ 408 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
130 M | $ 62.79 | -1.82 % | $ 3.41 B | ||
|
Pulmonx Corporation
LUNG
|
-36.1 M | $ 2.53 | 0.86 % | $ 99 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 14.56 | 0.76 % | $ 1.15 B | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 9.88 | 0.05 % | $ 709 M | ||
|
Myomo
MYO
|
-4.79 M | $ 1.06 | -1.85 % | $ 7.47 M | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 13.41 | -4.56 % | $ 1.03 B | ||
|
NuVasive
NUVA
|
-238 M | - | - | $ 2.07 B | ||
|
Align Technology
ALGN
|
-925 M | $ 165.15 | 0.78 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
73.7 M | $ 1.07 | -3.18 % | $ 110 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 12.81 | -1.23 % | $ 346 M | ||
|
Orthofix Medical
OFIX
|
77.8 M | $ 15.51 | -1.27 % | $ 591 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 14.86 | -0.03 % | $ 97.4 M | ||
|
AxoGen
AXGN
|
21.9 M | $ 30.33 | 1.15 % | $ 1.34 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
889 M | $ 40.78 | 2.33 % | $ 1.26 B | ||
|
LENSAR
LNSR
|
-13.6 M | $ 11.48 | -0.17 % | $ 132 M |